I

IX Biopharma Ltd
SGX:42C

Watchlist Manager
IX Biopharma Ltd
SGX:42C
Watchlist
Price: 0.119 SGD 8.18%
Market Cap: 113.8m SGD

Gross Margin
IX Biopharma Ltd

26.3%
Current
35%
Average
48.6%
Industry

Gross Margin is the amount of money a company retains after incurring the direct costs associated with producing the goods it sells and the services it provides. The higher the gross margin, the more capital a company retains, which it can then use to pay other costs or satisfy debt obligations.

Gross Margin
26.3%
=
Gross Profit
2m
/
Revenue
7.8m

Gross Margin Across Competitors

Country Company Market Cap Gross
Margin
SG
IX Biopharma Ltd
SGX:42C
105.7m SGD
26%
US
Eli Lilly and Co
NYSE:LLY
971.9B USD
83%
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP
56%
US
Johnson & Johnson
NYSE:JNJ
509.1B USD
68%
CH
Roche Holding AG
SIX:ROG
252.3B CHF
74%
UK
AstraZeneca PLC
LSE:AZN
208.5B GBP
82%
CH
Novartis AG
SIX:NOVN
202.4B CHF
76%
US
Merck & Co Inc
NYSE:MRK
249.5B USD
79%
DK
Novo Nordisk A/S
CSE:NOVO B
1.4T DKK
82%
IE
Endo International PLC
LSE:0Y5F
209B USD
68%
US
Pfizer Inc
NYSE:PFE
147B USD
75%
No Stocks Found

IX Biopharma Ltd
Glance View

Market Cap
105.7m SGD
Industry
Pharmaceuticals

iX Biopharma Ltd. engages in the development and commercialization of therapies for the treatment of acute and breakthrough pain, and other health conditions. The firm is focused on the development and commercialization of therapies for diseases of the central nervous system using patent protected formulations for sublingual delivery. The company developed a patented drug delivery platform technology, WaferiX. WaferiX delivers drug sublingually via the mucosa for better absorption, faster onset of action and predictable effect. Its delivery platform is particularly useful for drug repurposing. The firm operates in two segments, namely Specialty Pharmaceutical and Nutraceutical segments. Specialty Pharmaceutical primary business activities are the development, manufacturing and sale of pharmaceutical and nutraceutical products. Nutraceutical primary business activities are the sale of nutraceutical products. The firm's pipeline of products under development includes Wafermine (ketamine wafer) and BnoX (buprenorphine wafer) for pain management.

42C Intrinsic Value
0.033 SGD
Overvaluation 72%
Intrinsic Value
Price
I
What is Gross Margin?

Gross Margin is the amount of money a company retains after incurring the direct costs associated with producing the goods it sells and the services it provides. The higher the gross margin, the more capital a company retains, which it can then use to pay other costs or satisfy debt obligations.

Gross Margin
26.3%
=
Gross Profit
2m
/
Revenue
7.8m
What is the Gross Margin of IX Biopharma Ltd?

Based on IX Biopharma Ltd's most recent financial statements, the company has Gross Margin of 26.3%.

Back to Top